| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gastrointestinal Imaging |
1 From the Department of Diagnostic Radiology (H.B.M., P.L.C.), Surgery Branch (S.K.L., H.R.A., D.L.B.), Urologic Oncology Branch (M.M.W., W.M.L., G.M.G., P.L.C.), Genetic Epidemiology Branch (G.M.G.), and Surgical Neurology Branch (I.A.L.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm 1C660, Bethesda, MD 20892-1182. Received July 30, 2001; revision requested September 25; final revision received November 8; accepted May 14, 2002. Address correspondence to P.L.C. (e-mail: pchoyke@nih.gov).
PURPOSE: To demonstrate the imaging characteristics of neuroendocrine tumors (NETs) of the pancreas in patients with von Hippel–Lindau (VHL) disease to establish diagnostic criteria.
MATERIALS AND METHODS: Twenty-five patients with VHL disease and 29 surgically confirmed pancreatic NETs were included. Screening computed tomographic (CT) and/or magnetic resonance (MR) imaging findings were reviewed, and tumor number, diameter, growth rates (doubling time), location, presence of metastatic disease, and attenuation or enhancement properties were determined.
RESULTS: Eighteen of 29 (62%) pancreatic NETs were smaller than 3.0 cm in diameter and enhanced homogeneously on contrast material–enhanced CT and MR images. No tumor smaller than 3.0 cm metastasized. Tumors 3.0 cm or larger (11 [38%] of 29) more often enhanced heterogeneously, and two of 11 were associated with hepatic metastases. Smaller (<3.0 cm) tumors displayed longer mean doubling times (mean, 927 vs 351 days) than did larger (
3.0 cm) tumors; however, there was considerable overlap. Fifteen (52%) tumors were located in the pancreatic head; eight (28%), in the tail; and six (21%), in the body. Ten (40%) patients with pancreatic NETs had associated pheochromocytomas, and 22 (88%) had no or mild pancreatic cystic disease, which is substantially more than the general population of patients with VHL disease.
CONCLUSION: Pancreatic NETs in VHL have characteristic features at CT and MR imaging: Most are small, located in the pancreatic head, and enhance homogeneously. Tumors larger than 3.0 cm are prone to metastasize and enhance heterogeneously.
© RSNA, 2002
Index terms: Pancreas, neoplasms, 770.3191 • Pancreas, CT, 770.12112, 771.12114 • Pancreas, cysts, 770.31 • Pancreas, MR, 770.121411, 770.121412, 770.1214, 770.121415, 770.12143 • Pheochromocytoma, 86.328 • von Hippel–Lindau disease, 770.1834
This article has been cited by other articles:
|
|
 |
|
  A. Zhang, J. W. Sayre, L. Vachon, B. J. Liu, and H. K. Huang Racial Differences in Growth Patterns of Children Assessed on the Basis of Bone Age Radiology, October 27, 2008; (2008) 2493080468. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. S. Leung, S. V. Biswas, M. Duncan, and S. Rankin Imaging Features of von Hippel-Lindau Disease RadioGraphics, January 1, 2008; 28(1): 65 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. van Rijn, P. P. M. Schilte, B. M. Wiarda, J. A. J. M. Taminiau, and J. Stoker Case 113: Pancreatic Cystosis Radiology, May 1, 2007; 243(2): 598 - 602. [Full Text] [PDF]
|
|
|
|
 |
|
 E. R Woodward and E. R Maher Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr. Relat. Cancer, June 1, 2006; 13(2): 415 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Manoharan and M B Sheridan Neoplasms of the pancreas Imaging, September 1, 2004; 16(4): 323 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Taouli, M. Ghouadni, J.-M. Correas, P. Hammel, A. Couvelard, S. Richard, and V. Vilgrain Spectrum of Abdominal Imaging Findings in von Hippel-Lindau Disease Am. J. Roentgenol., October 1, 2003; 181(4): 1049 - 1054. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
